Navigation Links
Sangamo BioSciences Announces Presentation at the Lazard Capital Markets 8th Annual Healthcare Conference
Date:11/8/2011

RICHMOND, Calif., Nov. 8, 2011 /PRNewswire/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced today that Edward Lanphier, Sangamo's president and CEO, will provide an update on the progress of Sangamo's ZFP Therapeutic® development programs and an overview of the company's business strategy at 11:00 am ET on Tuesday, November 15, 2011 at the Lazard Capital Markets 8th Annual Healthcare Conference which will be held in New York City.

The presentation will be webcast live and may be accessed via a link on the Sangamo BioSciences website in the Investor Relations section http://investor.sangamo.com/index.cfm under Events and Presentations. The presentation will be archived on the Sangamo website for two weeks after the event.

About Sangamo

Sangamo BioSciences, Inc. is focused on research and development of novel DNA-binding proteins for therapeutic gene regulation and modification. Sangamo has a Phase 1/2 clinical trial and two ongoing Phase 1 clinical trials to evaluate safety and clinical effect of a treatment for HIV/AIDS as well as a Phase 1 trial of a treatment for recurrent glioblastoma multiforme. Other therapeutic development programs are focused on Parkinson's disease, monogenic diseases, neuropathic pain and nerve regeneration.  Sangamo's core competencies enable the engineering of a class of DNA-binding proteins called zinc finger DNA-binding proteins (ZFPs).  By engineering ZFPs that recognize a specific DNA sequence, Sangamo has created ZFP transcription factors (ZFP TFs) that can control gene expression and, consequently, cell function.  Sangamo is also developing sequence-specific ZFP Nucleases (ZFNs) for gene modification.  Sangamo has established strategic partnerships with companies in non-therapeutic applications of its technology including Dow AgroSciences and Sigma-Aldrich Corporation. For more information about Sangamo, visit the company's website at www.sangamo.com.

ZFP Therapeutic® is a registered trademark of Sangamo BioSciences, Inc.


'/>"/>
SOURCE Sangamo BioSciences, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Sangamo BioSciences Reports Third Quarter 2011 Financial Results
2. Sangamo BioSciences Announces Third Quarter 2011 Conference Call and Webcast
3. Sangamo BioSciences Announces Presentation at the 18th Annual Newsmakers in the Biotech Industry Conference
4. Sangamo BioSciences Announces Presentation at the 2011 UBS Global Life Sciences Conference
5. Sangamo BioSciences Reports Second Quarter 2011 Financial Results
6. Sangamo BioSciences Announces Efficient Generation of Transgenic Pigs Using Zinc Finger Nuclease (ZFN) Technology
7. Sangamo BioSciences Announces Second Quarter 2011 Conference Call and Webcast
8. Sangamo BioSciences Announces Presentation at Two Upcoming Investor Conferences
9. Sangamo Announces Pricing of Public Offering of Common Stock
10. Sangamo Announces Public Offering of Common Stock
11. Sangamo BioSciences and CHDI Foundation Announce Collaboration to Develop ZFP Therapeutic® for Huntingtons Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/26/2017)... ... 25, 2017 , ... Avery Products Corporation, the world’s largest ... printing, is proud to announce that it has won two more awards for ... at avery.com/GHS . The products were recently honored with the ASSE Safety ...
(Date:7/26/2017)... ... 25, 2017 , ... In this webinar , which ... considerations needed for designing ideal guide RNAs and DNA oligo or plasmid repair ... double-strand breaks in genomic DNA has greatly simplified strategies for precise gene editing ...
(Date:7/26/2017)... Jacksonville, FL (PRWEB) , ... July 26, 2017 ... ... deep learning algorithms targeted towards leveraging the years of diagnostic excellence by Mayo ... Logix. The first product suite will be distributed through the Microsoft Azure ...
(Date:7/26/2017)... July 26, 2017  Nurse practitioners play a crucial role ... of a Merck Manuals survey released today. The ... revealed that most (88 percent) believe they spend at least ... prescriptions. ... Merck Manuals survey of 210 nurse practitioners finds ...
Breaking Biology Technology:
(Date:4/11/2017)... -- Research and Markets has announced the addition of ... offering. ... market to grow at a CAGR of 30.37% during the period ... has been prepared based on an in-depth market analysis with inputs ... growth prospects over the coming years. The report also includes a ...
(Date:4/5/2017)... , April 5, 2017  The Allen Institute ... Allen Cell Explorer: a one-of-a-kind portal and dynamic digital ... 3D imaging data, the first application of deep learning ... human stem cell lines and a growing suite of ... platform for these and future publicly available resources created ...
(Date:4/3/2017)... April 3, 2017  Data captured by ... platform, detected a statistically significant association between ... to treatment and objective response of cancer ... to predict whether cancer patients will respond ... as well as to improve both pre-infusion potency ...
Breaking Biology News(10 mins):